NO20081847L - Fremgangsmate for a forbedre kognitiv funksjon - Google Patents
Fremgangsmate for a forbedre kognitiv funksjonInfo
- Publication number
- NO20081847L NO20081847L NO20081847A NO20081847A NO20081847L NO 20081847 L NO20081847 L NO 20081847L NO 20081847 A NO20081847 A NO 20081847A NO 20081847 A NO20081847 A NO 20081847A NO 20081847 L NO20081847 L NO 20081847L
- Authority
- NO
- Norway
- Prior art keywords
- cognitive function
- subject
- procedures
- improving cognitive
- homozygous
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71935305P | 2005-09-22 | 2005-09-22 | |
US72737705P | 2005-10-17 | 2005-10-17 | |
PCT/US2006/036603 WO2007038115A2 (fr) | 2005-09-22 | 2006-09-20 | Procede d'amelioration de la fonction cognitive |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20081847L true NO20081847L (no) | 2008-06-18 |
Family
ID=37876831
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20081847A NO20081847L (no) | 2005-09-22 | 2008-04-16 | Fremgangsmate for a forbedre kognitiv funksjon |
NO20081843A NO20081843L (no) | 2005-09-22 | 2008-04-16 | Farmasoytisk sammensetning for forbedret kognitiv funksjon |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20081843A NO20081843L (no) | 2005-09-22 | 2008-04-16 | Farmasoytisk sammensetning for forbedret kognitiv funksjon |
Country Status (16)
Country | Link |
---|---|
US (2) | US20080226719A1 (fr) |
EP (2) | EP1940403A2 (fr) |
JP (2) | JP2009508959A (fr) |
KR (2) | KR20080058413A (fr) |
AR (2) | AR055649A1 (fr) |
AU (2) | AU2006295010A1 (fr) |
BR (2) | BRPI0616192A2 (fr) |
CA (2) | CA2623210A1 (fr) |
CR (2) | CR9849A (fr) |
EA (2) | EA200800879A1 (fr) |
IL (2) | IL190217A0 (fr) |
MA (2) | MA29871B1 (fr) |
NO (2) | NO20081847L (fr) |
PE (2) | PE20070618A1 (fr) |
TW (2) | TW200803851A (fr) |
WO (2) | WO2007038115A2 (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080103165A1 (en) * | 2006-09-19 | 2008-05-01 | Braincells, Inc. | Ppar mediated modulation of neurogenesis |
IL187159A0 (en) * | 2007-07-03 | 2009-02-11 | Gur Megiddo | Use of metadoxine in relief of alcohol intoxication |
WO2009043593A1 (fr) * | 2007-10-05 | 2009-04-09 | Merz Pharma Gmbh & Co. Kgaa | Thérapie de combinaison utilisant la mémantine et les glitazones |
EP2085120A1 (fr) * | 2008-02-01 | 2009-08-05 | Merz Pharma GmbH & Co. KGaA | Utilisation de substances pour le traitement d'une déficience de récepteur d'insuline périphérique ou central et résistance à l'insuline |
US8846315B2 (en) * | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
ME01898B (me) | 2008-08-12 | 2014-12-20 | Zinfandel Pharmaceuticals Inc | Metoda za identifikaciju faktora rizika od alchajmerove bolesti |
US20100152249A1 (en) * | 2008-12-11 | 2010-06-17 | Board Of Trustees Of The Leland Stanford Junior University | Compositons and method for treatment of mood and cognitive impairments |
CN102481291B (zh) * | 2009-06-25 | 2015-10-21 | 阿尔考布拉有限公司 | 用于治疗、减轻症状、缓解、改善和预防认知疾病、障碍或病症的方法 |
US20100178307A1 (en) * | 2010-01-13 | 2010-07-15 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
US20130267560A1 (en) * | 2010-10-22 | 2013-10-10 | Cadila Healthcare Limited | Sustained release pharmaceutical compositions of donepezil |
MX358594B (es) * | 2011-01-10 | 2018-08-27 | Zinfandel Pharmaceuticals Inc | Factores de riesgo de enfermedad y métodos de uso. |
GEP201706786B (en) * | 2011-01-10 | 2017-12-11 | Takeda Pharmaceuticals Co | Methods and drug products for treating alzheimer's disease |
WO2013058409A1 (fr) | 2011-10-21 | 2013-04-25 | Takeda Pharmaceutical Company Limited | Préparation à libération prolongée |
US20140294724A1 (en) * | 2011-10-24 | 2014-10-02 | Intellect Neurosciences, Inc. | Compositions and methods for treatment of proteinopathies |
JPWO2014171542A1 (ja) * | 2013-04-19 | 2017-02-23 | 武田薬品工業株式会社 | 放出制御製剤 |
EP3490551A2 (fr) * | 2016-07-26 | 2019-06-05 | Ausio Pharmaceuticals, LLC | Méthodes de diagnostic et de traitement de la maladie d'alzheimer par s-équol |
US20180153859A1 (en) * | 2016-12-02 | 2018-06-07 | T3D Therapeutics, Inc. | Methods of treating or preventing cognitive impairment using indane acetic acid derivatives based on apoe4 genotype |
KR102224918B1 (ko) | 2018-03-20 | 2021-03-09 | (주)인벤티지랩 | 도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3265577B2 (ja) * | 1992-10-13 | 2002-03-11 | デューク・ユニバーシティ | アポリポ蛋白eの4型イソ型の測定法 |
US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
CA2355645A1 (fr) * | 1998-12-17 | 2000-06-22 | Mindset Biopharmaceuticals (Usa), Inc. | Utilisation accrue de glucose par le cerveau |
WO2005074917A1 (fr) * | 2004-01-30 | 2005-08-18 | Axonyx, Inc. | Methodes de traitement de complications du diabete |
-
2006
- 2006-09-20 TW TW095134700A patent/TW200803851A/zh unknown
- 2006-09-20 EA EA200800879A patent/EA200800879A1/ru unknown
- 2006-09-20 BR BRPI0616192-8A patent/BRPI0616192A2/pt not_active Application Discontinuation
- 2006-09-20 CA CA002623210A patent/CA2623210A1/fr not_active Abandoned
- 2006-09-20 US US12/067,382 patent/US20080226719A1/en not_active Abandoned
- 2006-09-20 JP JP2008532338A patent/JP2009508959A/ja active Pending
- 2006-09-20 EP EP06803887A patent/EP1940403A2/fr not_active Withdrawn
- 2006-09-20 US US12/067,374 patent/US20080262047A1/en not_active Abandoned
- 2006-09-20 WO PCT/US2006/036603 patent/WO2007038115A2/fr active Application Filing
- 2006-09-20 BR BRPI0616100-6A patent/BRPI0616100A2/pt not_active Application Discontinuation
- 2006-09-20 KR KR1020087009286A patent/KR20080058413A/ko not_active Application Discontinuation
- 2006-09-20 EA EA200800880A patent/EA200800880A1/ru unknown
- 2006-09-20 KR KR1020087009295A patent/KR20080056731A/ko not_active Application Discontinuation
- 2006-09-20 CA CA002623204A patent/CA2623204A1/fr not_active Abandoned
- 2006-09-20 TW TW095134699A patent/TW200803896A/zh unknown
- 2006-09-20 AU AU2006295010A patent/AU2006295010A1/en not_active Abandoned
- 2006-09-20 JP JP2008532341A patent/JP2009508960A/ja active Pending
- 2006-09-20 EP EP06815011A patent/EP1926488A2/fr not_active Withdrawn
- 2006-09-20 WO PCT/US2006/036597 patent/WO2007038112A2/fr active Application Filing
- 2006-09-20 AU AU2006295007A patent/AU2006295007A1/en not_active Abandoned
- 2006-09-21 PE PE2006001145A patent/PE20070618A1/es not_active Application Discontinuation
- 2006-09-21 PE PE2006001143A patent/PE20070976A1/es not_active Application Discontinuation
- 2006-09-25 AR ARP060104149A patent/AR055649A1/es unknown
- 2006-09-25 AR ARP060104148A patent/AR056527A1/es unknown
-
2008
- 2008-03-17 IL IL190217A patent/IL190217A0/en unknown
- 2008-03-17 IL IL190224A patent/IL190224A0/en unknown
- 2008-03-28 CR CR9849A patent/CR9849A/es not_active Application Discontinuation
- 2008-03-28 CR CR9848A patent/CR9848A/es not_active Application Discontinuation
- 2008-04-15 MA MA30849A patent/MA29871B1/fr unknown
- 2008-04-15 MA MA30850A patent/MA29872B1/fr unknown
- 2008-04-16 NO NO20081847A patent/NO20081847L/no not_active Application Discontinuation
- 2008-04-16 NO NO20081843A patent/NO20081843L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PE20070976A1 (es) | 2007-12-05 |
KR20080056731A (ko) | 2008-06-23 |
KR20080058413A (ko) | 2008-06-25 |
AU2006295010A1 (en) | 2007-04-05 |
WO2007038112A3 (fr) | 2007-12-06 |
WO2007038112A2 (fr) | 2007-04-05 |
AR056527A1 (es) | 2007-10-10 |
MA29871B1 (fr) | 2008-10-03 |
EA200800879A1 (ru) | 2008-10-30 |
BRPI0616100A2 (pt) | 2011-06-07 |
IL190224A0 (en) | 2008-11-03 |
BRPI0616192A2 (pt) | 2011-06-14 |
EP1940403A2 (fr) | 2008-07-09 |
CA2623204A1 (fr) | 2007-04-05 |
AU2006295007A1 (en) | 2007-04-05 |
AR055649A1 (es) | 2007-08-29 |
PE20070618A1 (es) | 2007-07-04 |
IL190217A0 (en) | 2008-11-03 |
JP2009508959A (ja) | 2009-03-05 |
JP2009508960A (ja) | 2009-03-05 |
CR9848A (es) | 2008-06-18 |
EA200800880A1 (ru) | 2009-02-27 |
MA29872B1 (fr) | 2008-10-03 |
US20080262047A1 (en) | 2008-10-23 |
WO2007038115A2 (fr) | 2007-04-05 |
EP1926488A2 (fr) | 2008-06-04 |
WO2007038115A3 (fr) | 2007-12-13 |
US20080226719A1 (en) | 2008-09-18 |
TW200803896A (en) | 2008-01-16 |
CR9849A (es) | 2008-05-21 |
NO20081843L (no) | 2008-06-16 |
TW200803851A (en) | 2008-01-16 |
CA2623210A1 (fr) | 2007-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20081847L (no) | Fremgangsmate for a forbedre kognitiv funksjon | |
Velez et al. | Characterization of renin-angiotensin system enzyme activities in cultured mouse podocytes | |
Buettner et al. | Development of prognostic factors and survival in cutaneous melanoma over 25 years: An analysis of the Central Malignant Melanoma Registry of the German Dermatological Society | |
Kezic et al. | Levels of filaggrin degradation products are influenced by both filaggrin genotype and atopic dermatitis severity | |
NO20090156L (no) | Humanisert antistoff | |
Azizi et al. | Comparison of salivary and plasma antioxidant levels in lichen planus patients and healthy subjects | |
Sundstroem et al. | Blood pressure levels and risk of cardiovascular events and mortality in type-2 diabetes: cohort study of 34 009 primary care patients | |
NO20061239L (no) | Fremgangsmater og reagenser for behandling av immunoinflammatoriske forstyrrelser | |
NO20082673L (no) | Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens | |
NO20070908L (no) | Sammensmeltede ringheterocykelkinasemodulatorer | |
NO20044562L (no) | Fremgangsmater for behandling av tarmslyng | |
NO20091926L (no) | Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer | |
ME00232B (me) | Antitijela za opgl | |
NO20061074L (no) | Forbindelser og sammensetninger som inbibitorer av reseptortyrosinkinaseaktivitet | |
NO20075821L (no) | Fremgangsmate til a oke testosteron- og beslektede steroidkonsentrasjoner hos kvinner | |
NO20073628L (no) | Pyridoner som er nyttige som inhibitorer av kinaser | |
HRP20050826B1 (hr) | Ciklički inhibitori proteinske tirozin kinaze | |
NO20064610L (no) | Identifikasjon av selv- og ikke selvantigener implisert i autoimmune sykdommer | |
DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
NO20075212L (no) | Samarbeidsrom | |
ATE548025T1 (de) | Inhalierbare zubereitungen zur behandlung pulmonarer hypertensie und methoden zu ihrer verwendung | |
NO20082216L (no) | Terapeutisk vaksine | |
NO20065232L (no) | 8-(2-hydroksyfenoksy)oktyldietanolamin og salter derav for avlevering av aktive forbindelser | |
NO20064325L (no) | Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes | |
ATE517340T1 (de) | Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |